Full Text View
Tabular View
Study Results
Related Studies
Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) Patients
This study has been completed.
Study NCT00677365   Information provided by Mpex Pharmaceuticals

First Received on May 12, 2008.   Last Updated on May 8, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Cystic Fibrosis (CF)
Additional conditions recognized in this trial
Cystic Fibrosis
Fibrosis
More general conditions related to this trial
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases
Interventions listed in this trial
MP-376
Placebo
Additional drug interventions recognized in this trial
Ofloxacin
More general drug interventions related to this trial
Anti-Bacterial Agents
Anti-Infective Agents
Anti-Infective Agents, Urinary
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Nucleic Acid Synthesis Inhibitors
Pharmacologic Actions
Renal Agents
Therapeutic Uses
Sponsors listed in this trial
Mpex Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services